Previous 10 | Next 10 |
TORONTO, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Trillium, "the company") (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced corporate restructuring to extend the company’s ...
TORONTO, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL) , a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has received a notification letter from The Nasdaq Stock Market LLC ("Nas...
TORONTO, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced the appointment of Mr. Jan Skvarka as President and Chief Executive Officer effective ...
TORONTO, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present at the following upcoming investor conf...
Trillium Therapeutics (NASDAQ: TRIL ): 1H GAAP EPS of -C$0.77. More news on: Trillium Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
TORONTO, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial results for the six months ended June 30, 2019. “We made excel...
FDA meeting scheduled to discuss the pivotal path for intratumoral TTI-621 in CTCL Intravenous TTI-621 protocol amended to enable dosing beyond 0.5 mg/kg and first patient cohort enrolling Enrollment in the first Simon’s 2-stage CTCL cohort in the TTI-621 intravenous study co...
TORONTO, July 02, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced the voting results from its Annual and Special Meeting of Shareholders held on June 27,...
TORONTO, July 02, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced the voting results from its Annual and Special Meeting of Shareholders held on June 27,...
Aduro Biotech ( ADRO -42.2% ) slumps on a 4x surge in volume in response to data presented at ASCO on STING candidate ADU-S100. More news on: Aduro BioTech, Inc., Novartis AG, Synlogic, Inc., Healthcare stocks news, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Trillium Therapeutics Inc. Company Name:
TRIL Stock Symbol:
NASDAQ Market:
Trillium Therapeutics Inc. Website:
The emerging psychedelics industry is expanding rapidly across the globe. With research demonstrating promising therapeutic potential for substance...
In this clip from "The Pharma & Biotech Show" on Motley Fool Live , recorded on Feb. 2 , Motley Fool contributors Keith Speights and Brian Orelli explain why the news of a discontinued drug from the pharmaceutical giant hasn't shaken investors. Keith Speights: Pf...
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL) , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is pleased to announce...